Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (NASDAQ: VRDN) has announced new employee stock option grants. The company approved non-qualified stock options for nine new employees totaling 113,200 shares on March 3, 2025. Additionally, newly appointed Chief Medical Officer Radhika Tripuraneni received options to purchase 310,700 shares effective March 10, 2025.
All grants will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments, subject to continued employment. These inducement grants were made outside the company's Equity Incentive Plan but follow its terms and conditions.
Viridian is advancing multiple treatments for thyroid eye disease (TED), including veligrotug (VRDN-001) in two global phase 3 trials (THRIVE and THRIVE-2), which have reported positive topline data. The company is also developing VRDN-003 in two phase 3 trials (REVEAL-1 and REVEAL-2) as a potential subcutaneous TED treatment, alongside a portfolio of FcRn inhibitors (VRDN-006 and VRDN-008) for autoimmune diseases.
Viridian Therapeutics (NASDAQ: VRDN) ha annunciato nuove concessioni di opzioni su azioni per i dipendenti. L'azienda ha approvato opzioni su azioni non qualificate per nove nuovi dipendenti per un totale di 113.200 azioni il 3 marzo 2025. Inoltre, il nuovo Chief Medical Officer Radhika Tripuraneni ha ricevuto opzioni per acquistare 310.700 azioni a partire dal 10 marzo 2025.
Tutte le concessioni matureranno nell'arco di quattro anni, con il 25% che matura dopo un anno e il resto in 36 rate mensili, soggette a continuazione dell'impiego. Queste concessioni di indennità sono state effettuate al di fuori del Piano di Incentivi Azionari dell'azienda, ma seguono i suoi termini e condizioni.
Viridian sta avanzando diversi trattamenti per la malattia oculare tiroidea (TED), inclusi veligrotug (VRDN-001) in due studi globali di fase 3 (THRIVE e THRIVE-2), che hanno riportato dati positivi preliminari. L'azienda sta anche sviluppando VRDN-003 in due studi di fase 3 (REVEAL-1 e REVEAL-2) come potenziale trattamento sottocutaneo per la TED, insieme a un portafoglio di inibitori di FcRn (VRDN-006 e VRDN-008) per malattie autoimmuni.
Viridian Therapeutics (NASDAQ: VRDN) ha anunciado nuevas concesiones de opciones sobre acciones para empleados. La empresa aprobó opciones sobre acciones no calificadas para nueve nuevos empleados que suman un total de 113,200 acciones el 3 de marzo de 2025. Además, el nuevo Director Médico Radhika Tripuraneni recibió opciones para comprar 310,700 acciones a partir del 10 de marzo de 2025.
Todas las concesiones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el resto en 36 cuotas mensuales, sujeto a la continuidad del empleo. Estas concesiones de incentivo se realizaron fuera del Plan de Incentivos de Capital de la empresa, pero siguen sus términos y condiciones.
Viridian está avanzando en múltiples tratamientos para la enfermedad ocular tiroidea (TED), incluyendo veligrotug (VRDN-001) en dos ensayos globales de fase 3 (THRIVE y THRIVE-2), que han informado datos positivos preliminares. La empresa también está desarrollando VRDN-003 en dos ensayos de fase 3 (REVEAL-1 y REVEAL-2) como un posible tratamiento subcutáneo para la TED, junto con un portafolio de inhibidores de FcRn (VRDN-006 y VRDN-008) para enfermedades autoinmunes.
Viridian Therapeutics (NASDAQ: VRDN)는 새로운 직원 주식 옵션 부여를 발표했습니다. 회사는 아홉 명의 새로운 직원을 위해 113,200주의 비자격 주식 옵션을 2025년 3월 3일 승인했습니다. 또한 새로 임명된 최고 의료 책임자 라디카 트리푸라넨이는 2025년 3월 10일부터 310,700주를 구매할 수 있는 옵션을 받았습니다.
모든 부여는 4년 동안 분할 지급되며, 1년 후에 25%가 분할 지급되고 나머지는 36개월에 걸쳐 매달 지급됩니다. 이러한 유인 부여는 회사의 주식 인센티브 계획 외부에서 이루어졌지만, 그 조건과 조항을 따릅니다.
Viridian은 갑상선 안구 질환(TED)에 대한 여러 치료법을 개발하고 있으며, veligrotug (VRDN-001)을 포함하여 두 개의 글로벌 3상 시험(THRIVE 및 THRIVE-2)에서 긍정적인 초기 데이터를 보고했습니다. 회사는 또한 TED의 잠재적인 피하 치료제로서 VRDN-003을 두 개의 3상 시험(REVEAL-1 및 REVEAL-2)에서 개발하고 있으며, 자가면역 질환을 위한 FcRn 억제제 포트폴리오(VRDN-006 및 VRDN-008)도 함께 개발하고 있습니다.
Viridian Therapeutics (NASDAQ: VRDN) a annoncé de nouvelles attributions d'options d'achat d'actions pour les employés. L'entreprise a approuvé des options d'achat d'actions non qualifiées pour neuf nouveaux employés totalisant 113 200 actions le 3 mars 2025. De plus, la nouvelle Directrice Médicale Radhika Tripuraneni a reçu des options pour acheter 310 700 actions à compter du 10 mars 2025.
Toutes les attributions seront acquises sur une période de quatre ans, avec 25 % acquises après un an et le reste en 36 versements mensuels, sous réserve de l'emploi continu. Ces attributions incitatives ont été effectuées en dehors du Plan d'Incentives en Actions de l'entreprise, mais respectent ses termes et conditions.
Viridian fait progresser plusieurs traitements pour la maladie oculaire thyroïdienne (TED), y compris le veligrotug (VRDN-001) dans deux essais mondiaux de phase 3 (THRIVE et THRIVE-2), qui ont rapporté des données préliminaires positives. L'entreprise développe également VRDN-003 dans deux essais de phase 3 (REVEAL-1 et REVEAL-2) comme traitement sous-cutané potentiel pour la TED, ainsi qu'un portefeuille d'inhibiteurs de FcRn (VRDN-006 et VRDN-008) pour les maladies auto-immunes.
Viridian Therapeutics (NASDAQ: VRDN) hat neue Aktienoptionsvergaben für Mitarbeiter angekündigt. Das Unternehmen genehmigte nicht qualifizierte Aktienoptionen für neun neue Mitarbeiter in Höhe von insgesamt 113.200 Aktien am 3. März 2025. Darüber hinaus erhielt die neu ernannte Chief Medical Officer Radhika Tripuraneni Optionen zum Kauf von 310.700 Aktien, die am 10. März 2025 in Kraft treten.
Alle Zuteilungen werden über vier Jahre fällig, wobei 25 % nach einem Jahr fällig werden und der Rest in 36 monatlichen Raten, vorbehaltlich einer fortgesetzten Beschäftigung. Diese Anreizvergaben wurden außerhalb des Aktienoptionsplans des Unternehmens vorgenommen, folgen jedoch dessen Bedingungen und Konditionen.
Viridian entwickelt mehrere Behandlungen für die Thyroid-Augenkrankheit (TED), einschließlich veligrotug (VRDN-001) in zwei globalen Phase-3-Studien (THRIVE und THRIVE-2), die positive vorläufige Daten berichtet haben. Das Unternehmen entwickelt auch VRDN-003 in zwei Phase-3-Studien (REVEAL-1 und REVEAL-2) als potenzielle subkutane TED-Behandlung, zusammen mit einem Portfolio von FcRn-Inhibitoren (VRDN-006 und VRDN-008) für Autoimmunerkrankungen.
- Positive topline data reported from both THRIVE and THRIVE-2 phase 3 trials
- Multiple advanced-stage drug candidates in development
- Successful attraction of key talent including new CMO
- None.
The New-Hire Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on March 3, 2025. The New-Hire Inducement Grants will vest over a four-year period, with
Viridian also announced that the company’s Board of Directors approved the grant of non-qualified stock options to Radhika Tripuraneni, who was recently appointed to the role of Chief Medical Officer (“CMO”), to purchase 310,700 shares of the company’s common stock (the “CMO Inducement Grant”) effective as of March 10, 2025 (the “CMO Grant Date”).
The CMO Inducement Grant has an exercise price per share that is equal to the closing price of Viridian’s common stock on the CMO Grant Date. The CMO Inducement Grant will vest over a four-year period, with
The New-Hire Inducement Grants and the CMO Inducement Grant have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan. The New-Hire Inducement Grants and the CMO Inducement Grant were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310719764/en/
Anabel Chan, 617-458-8725
Vice President, Investor Relations & Communications
IR@viridiantherapeutics.com
Louisa Stone, 617-272-4604
Senior Manager, Investor Relations & Communications
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
How many shares were granted in Viridian Therapeutics (VRDN) latest stock option grants?
What is the vesting schedule for VRDN's March 2025 inducement grants?
What clinical trials has Viridian Therapeutics (VRDN) reported positive results for?
What pipeline products is Viridian Therapeutics (VRDN) currently developing?
